WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8mPRNewsWire • 09/30/25
WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8mPRNewsWire • 09/29/25
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® LungBusiness Wire • 09/26/25
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025Business Wire • 09/17/25
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary NodulesBusiness Wire • 09/09/25
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross ProceedsBusiness Wire • 08/14/25
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross ProceedsBusiness Wire • 08/13/25
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test SalesBusiness Wire • 08/13/25
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test ResultsBusiness Wire • 07/29/25
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer DiagnosticBusiness Wire • 07/22/25
bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer DiagnosticBusiness Wire • 07/15/25
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics ConferenceBusiness Wire • 06/26/25
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer TherapyBusiness Wire • 06/24/25
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership BoardBusiness Wire • 06/11/25
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer TherapeuticsBusiness Wire • 05/28/25
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical OfficerBusiness Wire • 05/20/25
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung CancerBusiness Wire • 05/08/25
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m OfferingPRNewsWire • 05/07/25